Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
- PMID: 26943899
- PMCID: PMC4786416
- DOI: 10.7554/eLife.12626
Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
Abstract
The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of citations and Altmetric scores (Errington et al., 2014). This Registered Report describes the proposed replication plan of key experiments from "The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate" by Ward and colleagues, published in Cancer Cell in 2010 (Ward et al., 2010). The experiments that will be replicated are those reported in Figures 2, 3 and 5. Ward and colleagues demonstrate the mutations in isocitrate dehydrogenase 2 (IDH2), commonly found in acute myeloid leukemia (AML), abrogate the enzyme's wild-type activity and confer to the mutant neomorphic activity that produces the oncometabolite 2-hydroxyglutarate (2-HG) (Figures 2 and 3). They then show that elevated levels of 2-HG are correlated with mutations in IDH1 and IDH2 in AML patient samples (Figure 5). The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange and the results of the replications will be published by eLife.
Keywords: 2-HG; IDH1; IDH2; Reproducibility Project: Cancer Biology; acute myeloid leukemia; biochemistry; cell biology; human; methodology.
Conflict of interest statement
OF: West Coast Metabolomics Center is a Science Exchange associated laboratory.
MRS: West Coast Metabolomics Center is a Science Exchange associated laboratory.
The other authors declare that no competing interests exist.
RP:CB: EI, FT, JL, NP: Employed by and hold shares in Science Exchange Inc.
Similar articles
-
Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.Elife. 2015 Jul 31;4:e07420. doi: 10.7554/eLife.07420. Elife. 2015. PMID: 26231040 Free PMC article.
-
Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.Elife. 2017 Jun 27;6:e26030. doi: 10.7554/eLife.26030. Elife. 2017. PMID: 28653623 Free PMC article.
-
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.Cancer Cell. 2010 Mar 16;17(3):225-34. doi: 10.1016/j.ccr.2010.01.020. Epub 2010 Feb 18. Cancer Cell. 2010. PMID: 20171147 Free PMC article.
-
IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.Clin Cancer Res. 2012 Oct 15;18(20):5562-71. doi: 10.1158/1078-0432.CCR-12-1773. Clin Cancer Res. 2012. PMID: 23071358 Free PMC article. Review.
-
IDH mutations in cancer and progress toward development of targeted therapeutics.Ann Oncol. 2016 Apr;27(4):599-608. doi: 10.1093/annonc/mdw013. Ann Oncol. 2016. PMID: 27005468 Review.
Cited by
-
Metabolism-Relevant Molecular Classification Identifies Tumor Immune Microenvironment Characterization and Immunotherapeutic Effect in Cervical Cancer.Front Mol Biosci. 2021 Jul 1;8:624951. doi: 10.3389/fmolb.2021.624951. eCollection 2021. Front Mol Biosci. 2021. PMID: 34277697 Free PMC article.
-
Metabolism-associated molecular classification of hepatocellular carcinoma.Mol Oncol. 2020 Apr;14(4):896-913. doi: 10.1002/1878-0261.12639. Epub 2020 Jan 29. Mol Oncol. 2020. PMID: 31955511 Free PMC article.
-
Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications.Aging (Albany NY). 2020 Mar 22;12(6):4970-4995. doi: 10.18632/aging.102923. Epub 2020 Mar 22. Aging (Albany NY). 2020. PMID: 32201399 Free PMC article.
-
Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment.Int J Hematol. 2022 Sep;116(3):330-340. doi: 10.1007/s12185-022-03416-7. Epub 2022 Jul 16. Int J Hematol. 2022. PMID: 35841458 Review.
-
Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy.Front Immunol. 2022 Sep 8;13:991656. doi: 10.3389/fimmu.2022.991656. eCollection 2022. Front Immunol. 2022. PMID: 36211409 Free PMC article.
References
-
- Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–744. doi: 10.1038/nature08617. - DOI - PMC - PubMed
-
- Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJM, Thompson CB, Levine RL, Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553–567. doi: 10.1016/j.ccr.2010.11.015. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
